Cronos (CRO) fell toward the $0.056 price area on October 22, giving back most of its recent recovery. The daily chart showed the token near $0.05609, down about 3.69% from its starting price for the day.
The pullback leaves buyers defending the $0.055–$0.056 zone while another scheduled token release approaches in November. Holding this range could allow for a fresh recovery attempt, but CRO still faces a hurdle near $0.060.
Recovery runs into trouble
CRO climbed toward $0.070 in late September, but that advance gave way to a steady October decline as it failed to hold those levels. Recent recovery attempts have struggled around $0.058–$0.059, and the latest move brought the price back toward the lower end of its recent trading range.
CRO also traded below its displayed moving averages. Three of those lines were around $0.060, making that area a potential obstacle to recovery.
Trading volume has dropped compared with September’s rally, indicating quieter participation and no evidence of a strong return of buying.
Another token unlock approaches
Data from Tokenomist shows that about 1.2 billion CRO was unlocked from the Cronos Strategic Reserve on October 17, representing about 2.3% of the circulating supply. Another release of about the same size is set to occur on November 16, according to Tokenomist.
These figures add context to the supply increase expected in the coming weeks, but an unlock does not mean the tokens were sold. CRO’s decline also began before October 17, so the broader price fall and the unlock are not likely to be related.
Tokenomist separately reports that 228 million CRO were burnt over the past 30 days.
Levels that could shape CRO’s next move
The immediate question is whether CRO can hold $0.055–$0.056. A close around that area could lead to further weakness, followed by difficulty recovering it. If that happens, CRO could find support around $0.053–$0.054.
For a recovery, CRO would first need to move to $0.058 and then $0.060. Holding above the latter would improve its trend and bring $0.065 into consideration.
For now, CRO remains below those recovery levels, and buyers are finding it hard to establish a sustained turnaround.
